For instance, PROTACs have shown efficacy in degrading oncogenic fusion proteins like BCR-ABL in chronic myeloid leukemia, thereby circumventing resistance mechanisms often encountered with kinase inhibitors [137]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.